Decapeptyl®, Neo Decapeptyl®, Trelstar®, Pamorelin®, Triptodur®

Triptorelin is a gonadotropin releasing hormone (GnRH) agonist

Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur®, is a GnRH agonist analogue. An agonist is a chemical that binds to a receptor of a cell and triggers a response by that cell. Triptorelin decreases the serum testosterone to castrate levels (estradiol in females).

Androgen deprivation stops the growth of the androgen dependent prostate cancer, alleviating pain and improving thus the quality of life of patients. GnRH agonist treatment achieves similar overall survival rates in advanced prostate cancer as surgical castration.The triptorelin 1-month, 3-month and 6-month sustained release formulations have provided patients with a convenient treatment modality.

In short

GnRH discovered by Professor Andrew Schally (1971 - Tulane University), who received the Nobel Prize in 1977 for his discovery. The first synthesis of GnRH agonist Triptorelin by Professor Andrew Schally was in 1973.

Triptorelin is number one product of Ipsen in 2014.

Overview of the products


  • Advanced prostate cancer
  • Endometriosis
  • In-vitro fertilization programs
  • Uterine fibroids
  • Precocious puberty

Product Characteristics

3 dosages:

  • 1-month (3.75 mg)
  • 3-month (11.2 mg)
  • 6-month (22.5 mg)

Debiopharm Value Added

  • Development and registration of the triptorelin 1-, 3- and 6-month sustained release formulations in Europe, in North America and the rest of the world
  • Continuous life cycle management (new formulations, route of administration, indications)
  • First worldwide registered sustained release formulation of a gonadotropin releasing hormone (GnRH) agonist in 1986.

Commercial map

Press Releases

All Triptorelin related press releases

Selected Publications

All Triptorelin related publications